The Federal Trade Commission (FTC), together with Alaska, Iowa, Nebraska, and Texas, initiated legal action against the World Professional Association for Transgender Health (WPATH), accusing the organization of facilitating false representations regarding gender-affirming treatments for children. The lawsuit claims WPATH’s published standards provide a framework that allows medical providers to promote puberty blockers, hormone therapies, and surgical interventions as safe and necessary despite insufficient evidence backing these assertions.
The complaint highlights concerns about WPATH’s 2022 Standards of Care (SOC-8), which allegedly excluded explicit age limits for irreversible procedures such as chest reconstruction and genital surgeries. The FTC contends this omission violates the Federal Trade Commission Act by enabling deceptive marketing practices toward parents considering medical treatments for their transgender children.
Founded in 1979 as the Harry Benjamin International Gender Dysphoria Association, WPATH has become an influential nonprofit publishing clinical guidelines for transgender and gender-diverse health care worldwide. Its latest SOC-8 guidelines, released in September 2022, serve as a widely referenced clinical benchmark among insurers, hospitals, and health care providers treating transgender patients.
This lawsuit escalates an ongoing dispute surrounding gender-affirming care, following WPATH’s prior efforts to block an FTC civil investigative demand into its practices. In February, WPATH sued the FTC, accusing the federal agency of conducting a politically motivated crackdown that threatens medical autonomy and freedom of speech. WPATH maintains its care standards rely on scientific evidence, expert consensus, and patient-centered values.
The legal challenge now confronting WPATH raises broader questions about regulatory oversight of transgender health protocols, particularly concerning minors. Should courts rule against the organization, the resulting impact could reshape access to gender-affirming therapies across the United States, potentially altering how care is defined and delivered nationwide.